These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28515255)

  • 1. Active Systemic Treatment of Pancreatic Cancer.
    Tempero M
    J Natl Compr Canc Netw; 2017 May; 15(5S):723-725. PubMed ID: 28515255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
    Kwon D; McFarland K; Velanovich V; Martin RC
    Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy.
    Evans DB; George B; Tsai S
    Ann Surg Oncol; 2015 Oct; 22(11):3409-13. PubMed ID: 26122369
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer.
    Polish A; Joseph NE; Marsh RW
    Am J Clin Oncol; 2019 Oct; 42(10):761-766. PubMed ID: 31569128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer?
    Kelly KN; Macedo FI; Merchant NB
    Adv Surg; 2020 Sep; 54():49-68. PubMed ID: 32713439
    [No Abstract]   [Full Text] [Related]  

  • 6. Neoadjuvant therapy for resectable pancreatic cancer.
    Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
    Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
    Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
    Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?
    Reni M
    World J Gastroenterol; 2010 Oct; 16(39):4883-7. PubMed ID: 20954273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
    Hackert T; Ulrich A; Büchler MW
    Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
    [No Abstract]   [Full Text] [Related]  

  • 10. [Neoadjuvant therapy vs. upfront resection for resectable pancreatic cancer].
    Strobel O; Büchler MW
    Chirurg; 2017 Jul; 88(7):619. PubMed ID: 28573533
    [No Abstract]   [Full Text] [Related]  

  • 11. Multimodality management of borderline resectable pancreatic adenocarcinoma.
    Prakash LR; Katz MHG
    Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of surgery in pancreatic cancer.
    Buanes TA
    World J Gastroenterol; 2017 Jun; 23(21):3765-3770. PubMed ID: 28638216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
    J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
    Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma.
    Blair AB; Sorber R; Rozich NS; Burkhart RA
    Pancreas; 2019 Sep; 48(8):973-984. PubMed ID: 31425483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
    de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
    Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approach to patients with pancreatic cancer without detectable metastases.
    Heestand GM; Murphy JD; Lowy AM
    J Clin Oncol; 2015 Jun; 33(16):1770-8. PubMed ID: 25918279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant
    Hashmi A; Kozick Z; Fluck M; Hunsinger MA; Wild J; Arora TK; Shabahang MM; Blansfield JA
    Am Surg; 2018 Sep; 84(9):1439-1445. PubMed ID: 30268172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.